APPLICATIONS
Therapy dedicated to depigmentation disorders associated with inflammatory skin diseases such as:
- Vitiligo: most common depigmenting disorder (0.5-1% of the world population)
- Stigma and major negative impact on patients’ quality of life
- No cure nor way of restricting the spread of the disease reported so far
- Sclerodermia, Psoriasis, Atopic dermatitis: often associated with pigmentation disorders responsible of impact on quality of life
DESCRIPTION
- Identification of a core molecule X1 involved in melanocytes detachment responsible for depigmentation in vitiligo and post-inflammatory skin disorders
- Ex vivo analysis
- Higher X1 expression in vitiligo patients’ skin and sera compared to healthy subjects−Vitiligo patients: Positive correlation between X1 level and the body surface area involved
- POC in vitro:
- Inhibitors targeting X1 prevent melanocyte detachment in a 3D-induced depigmentation model
BENEFITS
- Development of the first targeted therapy dedicated to inflammatory skin disorders with high unmet medical needs
- Near-orphan status for drug development
- Application to diverse inflammatory skin disorders associated with depigmentation
- Vitiligo
- Scleroderma, Psoriasis and Atopic Dermatitis
IP
This technology is protected by a patent application